A. Borel‐derlon

F. Beygui, K. Blanchart, R. Sabatier, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study

K. Baumstarck, P. Auquier, T. Lambert, 2018, BMJ Open.

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

D. Huet, P. Morange, S. Susen, 2020, Critical Care.

Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

P. Morange, S. Susen, S. Laporte, 2021, Anaesthesia Critical Care & Pain Medicine.

inhibitors in previously untreated patients with severe hemophilia A Influence of the type of factor VIII concentrate on the incidence of factor VIII

T. Lambert, C. Rothschild, A. Borel‐Derlon, 2013 .

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

T. Lambert, C. Rothschild, A. Borel‐Derlon, 2006, Blood.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis

P. Lenting, S. Susen, F. Vincent, 2016, Thrombosis and Haemostasis.

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

P. Mannucci, A. Borel‐Derlon, J. Goudemand, 2005, Journal of thrombosis and haemostasis : JTH.

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres

J. Blatny, G. Auerswald, M. Morfini, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

T. Lambert, A. Borel‐Derlon, Y. Gruel, 2018, Vox sanguinis.

Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors

A. Borel‐Derlon, P. Gautier, M. Brionne, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

P. Moreau, T. Lambert, C. Rothschild, 2006, Seminars in hematology.

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

P. Mannucci, C. Rothschild, A. Borel‐Derlon, 2007, Journal of thrombosis and haemostasis : JTH.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease

C. Denis, S. Susen, A. Borel‐Derlon, 2016, Medicine.

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia

X. Troussard, A. Aouba, A. Borel‐Derlon, 2016, Medicine.

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

E. Neufeld, T. Lambert, M. Carcao, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

F376A/M388A‐solulin, a new promising antifibrinolytic for severe haemophilia A

D. Vivien, A. Borel‐Derlon, J. Parcq, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A

V. Ramanan, F. Rosendaal, S. Kaveri, 2019, Haematologica.

Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost – the ‘Statut Orthopédique des Patients Hémophiles’ avec Inhibiteur study

T. Lambert, M. Bertrand, A. Borel‐Derlon, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

EQOFIX: a combined economic and quality‐of‐life study of hemophilia B treatments in France

C. Rothschild, A. Borel‐Derlon, J. Goudemand, 2015, Transfusion.

Patient resources in the therapeutic education of haemophiliacs in France: their skills and roles as defined by consensus of a working group

T. Lambert, A. Borel‐Derlon, S. Meunier, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

S. Susen, A. Harroche, A. Borel‐Derlon, 2020, Journal of thrombosis and haemostasis : JTH.